A Phase 3 interventional study of hypothermia in Ischemic Stroke, Large Vessel Occlusion and Endovascular Treatment, sponsored by University of Freiburg. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-06.
Sponsored by University of Freiburg · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.
Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 39th largest by planned enrollment of the 101 interventional ones that give a count, is one of 7 that started in 2024, is one of 20 in phase 3, reaches primary completion later than 13 of the 49 other live ones, and was the 142nd registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:
Ludwig-Maximilians - University of Munich · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Charite University, Berlin, Germany · Sites in Germany
Giuseppe Tarantini · Sites in Germany
Ages 18–65
Takeda · Sites in Germany, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 33 · Phase 3 22 · Phase 4 4
First in 2000; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 223 across the 101 interventional studies, 410 across the 61 observational. Of the 98 that completed or were terminated, 25 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 164 have an industry lead sponsor. The 10 most frequent:
University of Freiburg is the lead sponsor of 27 studies on the registry; 5 are open to participants now.
University of Freiburg has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
14 of the studies in Ischemic Stroke with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT06121336Ludwig-Maximilians - University of MunichPRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke | 2026-12-31 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT04412187Martin DichgansInflammatory faCtors AfteR acUte Ischemic Stroke | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 164 studies in Ischemic Stroke with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test the combination of hypothermia and endovascular treatment in acute stroke patients with large vessel occlusion.
The main question it aims to answer is: does an additional cooling to 35°C result in a benefit on clinical outcome ? Participants receive immediate cooling using a noninvasive transnasal cooling technique (RhonoChill) and are maintained at 35°C for 6 hours after reopening of the vessel using surface cooling, and then slowly rewarmed.
Researchers will compare the intervention group (hypothermia and endovascular treatment and best medical treatment including iv thrombolysis) and control group (only endovascular treatment and best medical treatment including iv thrombolysis) to see if additional hypothermia leads to a better outcome after 3 months without relevant complications.
Despite the well-established benefit of endovascular treatment (EVT) for acute ischemic stroke due to large vessel occlusion (LVO), more than half of patients treated with EVT remain functionally dependent despite high reperfusion rates. Thus, new strategies such as additional neuroprotection using hypothermia need to be explored, first to bridge time to reperfusion and second, to attenuate reperfusion injury.
Although therapeutic hypothermia has consistently demonstrated robust neuroprotection in animal ischemic-reperfusion models, randomized trials in acute stroke patients have failed to demonstrate the efficacy of induced hypothermia. The reasons for this treatment failure are diverse and include treatment delay, the unfeasibility of inducing and maintaining hypothermia due to intolerance and shivering in awake patients, the missing recanalization in a large proportion of patients, the heterogeneity of patients included, and too deep (32-34°C) hypothermia associated with an increase in side effects.
In the pilot study COTTIS-1, we could demonstrate the feasibility and safety of immediately induced intraischemic hypothermia to 35°C with non-invasive transnasal cooling by RhinoChill® (BrainCool) followed by surface cooling for 6h after recanalization in sedated and intubated patients with LVO undergoing EVT. By combining this cooling technique with thrombectomy we have tried to address the above mentioned reasons for hypothermia failure. In COTTIS-1, the target temperature of 35°C was reached within 30 min, corresponding to a cooling rate of 2.6°C/h. All patients reached the target temperature, and 86% of the patients had reached ≤35°C at recanalization by thrombectomy. 68% of patients had a good outcome (independency) after 3 months. There were only asymptomatic side effects during hypothermia.
As a consequence, the present COTTIS-2 study is planned to evaluate the efficiency of this cooling protocol in a multicentric, randomized, controlled, end-point-blinded study in Germany.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Time window 0-24h:
Last seen normal to groin puncture 6-24h or unknown time window: significant mismatch imaging according to the eligibility criteria of the DEFUSE-3 trial
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
standard endovascular treatment (EVT) for large vessel occlusion (LVO) without hypothermia
standard endovascular treatment (EVT) for large vessel occlusion (LVO) combined with hypothermia
Device: hypothermia
hypothermia is started after intubation for endovascular treatment and induced by transnasal cooling (RhinoChill) to a target temperature of 35°C and hypothermia is then maintained at 35°C for 6 hours after recanalisation by surface cooling followed by slow rewarming by 0.2°C per hour to 36.5°C
functional outcome
The presence of patients with good neurological outcome after 3 months as defined by modified Rankin Scale (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death) of 0-2 or back to baseline before stroke
Time frame: 3 months
infarction volume
Infarction volume assessed in the standard CT 24 hours after thrombectomy
Time frame: 24 hours
increase in infarction
increase of the infarct core based on imaging at the time of admission (DWI-MRI or CBF\<30% of contralateral side at CT-Perfusion) and CT after 24 hours
Time frame: 24 hours
recanalization result
Recanalization result (by mTICI score: successful recanalization mTICI 2b-3) after thrombectomy (based on angiography during/after thrombectomy) and 24 hours after thrombectomy (based on ultrasound of the cerebral vessels)
Time frame: after thrombectomy and 24 hours
neurological improvement
Change of at least 8 points on the National Institutes of Health Stroke Scale (NIHSS; on which scores range from 0 to 42, with higher scores indicating a greater deficit) at 48 hours after thrombectomy
Time frame: 48 hours
outcome at discharge
modified Rankin Score (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death) upon discharge/transfer in rehabilitation
Time frame: up to 3 months
shift in functional outcome
ordinal shift across the range of modified Rankin Score (mRS; on which scores range from 0 to 6, with 0 means no symptoms and 6 means death)
Time frame: 3 months
very good clinical outcome
Presence of patients with very good clinical outcome after 3 months (mRS 0-1)
Time frame: 3 months
mortality
Mortality during acute hospitalisation and after 3 months
Time frame: 3 months
Length of ventilation
Length of mechanical ventilation
Time frame: 3 months
Length of stay
Length of ICU stay and hospital stay
Time frame: 3 months
body temperature
Temperature at admission, at recanalization, and first 6 hours after recanalization, and at 24 hours
Time frame: 24 hours
time to groin puncture
Time from arrival until groin puncture
Time frame: baseline, pre-intervention
time to recanalization
Time from arrival until recanalization
Time frame: periprocedurally
Occurrence of intracerebral haemorrhage (ICH)
* Any ICH (subarachnoid, intraparenchymal, intraventricular) on the CT after 24 hours * Symptomatic ICH (defined according to SITS-MOST criteria): Hematoma \>30% of initial infarction volume associated with a clinical deterioration in NIHSS score of at least 4 points within 24 hours after thrombectomy
Time frame: 24 hours
Complications associated with hypothermia
* Nosebleed and pailing of the nose * Periorbital emphysema * Pneumocephalus (in 24-hour control CT) * Blood pressure, heart rate, oxygen saturation SO2 * Episodes with severe hypotension with systolic blood pressure \<110mmHg * Incidence of pneumonia (defined as: any new pulmonary infiltrate on radiographic imaging occurring \<48hrs after admission combined with at least one of the subsequent findings: fever \>38°C, leukopenia/leucocytosis, purulent secretions with positive cultures) * Disturbances in electrolytes, renal function, coagulation (potassium, sodium, chloride, creatinine, INR, pTT, thrombocytes measured on admission before hypothermia and at 24 hours)
Time frame: 24hours
Plan to share: Yes — Individual patient data (after anonymization), on which the results of the present study are based, can be made available to scientists upon request (methodologically meaningful evaluation proposal approved by a committee specifically appointed for this evaluation proposal) (6 months to 36 months after publication of the study)
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: 6 months to 36 months after publication of the study
Access criteria: upon request of scientists with methodologically meaningful evaluation proposal approved by a committee specifically appointed for this evaluation proposal
Started Jul 2024 (actual). Primary completion is estimated for Mar 2026, 20 months after the start.
Of 145 non-industry phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 20 months is below that.
Counting every sponsor, half of 167 studies reached it within 30 months; a quarter within 19 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Freiburg